Related Experiment Video
Updated: Jun 21, 2025
14:35
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.5K
Multimorbidity in Incident Heart Failure: Characterisation and Impact on 1-Year Outcomes
Anyuli Gracia Gutiérrez1,2, Aida Moreno-Juste3,4,5, Clara Laguna-Berna3
1Internal Medicine Service, Defense General Hospital, Vía Ibérica 1, ES-50009 Zaragoza, Spain.
Journal of Clinical Medicine
|July 13, 2024
Summary
Mental health comorbidities significantly impact heart failure (HF) patients, increasing mortality and hospitalizations. A comprehensive approach to managing all patient conditions is crucial for better HF outcomes.
Area of Science:
- Cardiology
- Geriatrics
- Public Health
Background:
- Heart failure (HF) frequently co-occurs with multiple comorbidities, significantly affecting patient well-being and healthcare resource utilization.
- Understanding the interplay between HF and various comorbidities is essential for effective patient management and system-level planning.
Purpose of the Study:
- To analyze the demographic and clinical profiles of patients newly diagnosed with heart failure.
- To investigate the impact of different comorbidity clusters on one-year health outcomes in incident heart failure patients.
Main Methods:
- Retrospective, population-based observational study using the EpiChron Cohort in Spain (2014-2018).
- Inclusion of all primary and hospital care patients diagnosed with HF.
- Chronic diseases were categorized into cardiovascular, mental, and other physical clusters for analysis using Cox regression models and survival curves.
Main Results:
- 13,062 incident HF patients identified (mean age 82.0 years, 54.8% women, 93.7% multimorbid).
- One-year follow-up revealed 25.3% mortality and 35.4% all-cause hospitalizations.
- Mental comorbidity cluster independently associated with increased risk of death (HR 1.08) and all-cause hospitalization (HR 1.09) after adjustment.
Conclusions:
- Contrary to common assumptions, cardiovascular comorbidities are not the strongest predictors of adverse outcomes in HF patients.
- Mental health comorbidities present a significant risk factor for poor health outcomes in heart failure.
- A holistic, integrated approach considering the full spectrum of comorbidities is vital for optimizing heart failure management.
More Related Videos
Related Concept Videos
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:22Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
01:22Heart Failure Drugs: Diuretics
362
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
362
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
01:26Heart Failure Drugs: Inotropic Agents
564
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564
01:26Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K